rethinkPeptides Search
Menu
Home / Research library
Study breakdown

GLP-1 Drugs Not Associated with Increased Colon Cancer Risk in Diabetic Adults

RPEP-152372026Guo, Man; Liu, Yong; Zeng, Yan; Chen, Jiao; Zeng, Chen; Huang, Lin-Lin; Wang, Ji-Ying; Wu, Yang-Hao-Tian; Wu, Qi; Teng, Fang-Yuan; Xu, Yong
evidence
The takeaway

GLP-1 receptor agonist use was not associated with increased colon cancer risk in adults with type 2 diabetes, providing safety reassurance for this common concern.

No cancer signal

GLP-1 drug use was not linked to increased colon cancer risk, adding to cancer safety evidence for this drug class

What the researchers found

GLP-1 RA use was not associated with increased risk of colon cancer in adults with type 2 diabetes.

Why it matters

Cancer safety is a major concern for drugs used by millions of people long-term. This evidence provides reassurance for one of the most common cancer types.

How the study worked

Cohort study evaluating the association between GLP-1 RA use and colon cancer risk in T2D adults.

What this study cannot tell us

Observational design. Colon cancer develops over decades; follow-up may be insufficient. Cannot completely rule out very small risk increases.

How to read the evidence

Observational cohort study. Reassuring negative finding consistent with other cancer safety analyses.

When this study was published

Published in 2025.

The bigger picture

Accumulating evidence consistently shows GLP-1 drugs do not increase cancer risk, and some studies suggest potential protective effects.

Questions still open

  • Could GLP-1 drugs actually protect against colon cancer through anti-inflammatory mechanisms?
  • Do longer-term studies confirm neutral or protective effects?
  • Should cancer screening recommendations change for long-term GLP-1 users?

Common questions

Do GLP-1 drugs cause colon cancer?
No. This study found no association between GLP-1 drug use and colon cancer in diabetic adults, consistent with other cancer safety studies for this drug class.
Should I get extra cancer screening while on GLP-1 drugs?
There is no evidence that GLP-1 drugs increase cancer risk. Standard age-appropriate cancer screening is recommended; no additional screening is needed because of these medications.

Read the original research

Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.

Diabetes/metabolism research and reviews, 42(2), e70134

View on PubMed ↗Publisher’s paper ↗

Citation

Guo, Man; Liu, Yong; Zeng, Yan; Chen, Jiao; Zeng, Chen; Huang, Lin-Lin; Wang, Ji-Ying; Wu, Yang-Hao-Tian; Wu, Qi; Teng, Fang-Yuan; Xu, Yong. (2026). Association Between GLP-1 Receptor Agonists and the Risk of Colon Cancer in Adults With Type 2 Diabetes or Obesity: A Systematic Review and Network Meta-Analysis.. Diabetes/metabolism research and reviews, 42(2), e70134. https://doi.org/10.1002/dmrr.70134